Editorials: fusion inhibition--a major but costly step forward in the treatment of HIV-1

The high cost is attributed to a complex and protracted manufacturing process and will probably not change until alternative HIV-1 entry inhibitors, possibly including orally administered agents, have earned FDA approval. Because of production constraints, the drug will be available to no more than...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 348; no. 22; p. 2249
Main Authors Tashima, Karen T, Carpenter, Charles CJ
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 29.05.2003
Subjects
Antiretroviral drugs
HIV
Human immunodeficiency virus
Mutation
Patients
Online AccessGet full text

Cover

More Information
Summary:The high cost is attributed to a complex and protracted manufacturing process and will probably not change until alternative HIV-1 entry inhibitors, possibly including orally administered agents, have earned FDA approval. Because of production constraints, the drug will be available to no more than 15,000 persons worldwide during the next 12 months.
ISSN:0028-4793
1533-4406